PRCXI
Home > News > Corporate Information >
PRCXI Secures Tens of Millions of Yuan in Series A+ Funding from CICC Capital to Accelerate Smart Lab-Driven R&D Paradigm Upgrade

Release time: 2026-01-05

Leading enterprise in life science automation, Suzhou PRCXI Bioinformation Co., Ltd. (hereinafter referred to as "PRCXI") announced on December 31, 2025
Leading enterprise in life science automation, Suzhou PRCXI Bioinformation Co., Ltd. (hereinafter referred to as "PRCXI") announced on December 31, 2025, the completion of a tens of millions of yuan Series A+ financing round exclusively invested by funds under CICC Capital.

Notably, this follows the company’s previous investments from institutions such as China Securities Capital and Qiming Venture Partners, marking another endorsement from top-tier capital within just a few months. The continuous capital recognition not only affirms PRCXI’s past achievements but also reflects high approval of its "Smart Lab" ecosystem strategy and business model.




The funds raised in this round will be primarily used to deepen the development of PRCXI’s core artificial intelligence models and algorithms, upgrade its leading automated workstation and instrument product lines, and further advance the comprehensive implementation and continuous optimization of the Smart Lab.


Unique Approach: Building a Solid Foundation for the Smart Lab with "Intelligent Genes"
Different from traditional laboratory integrator models, PRCXI is committed to a robust development path of "Artificial Intelligence + Automated Equipment + Full In-house Manufacturing." With its proprietary AI models serving as the intelligent core, the company has achieved full-chain closed-loop production—from core component R&D and precision machining to complete machine assembly. Moreover, intelligent algorithms are deeply integrated into the entire product development and manufacturing process, ensuring technological leadership and system reliability.




Business Advancement: From Deep Co-creation to Replicable Smart Lab Units

At the commercial level, PRCXI has not limited itself to equipment sales but has chosen to engage in deep co-creation with leading players in cutting-edge fields such as synthetic biology and genomics. Leveraging its full-chain automated equipment delivery capabilities and the precise execution of software algorithms, the company has successfully validated an efficient delivery model of "joint R&D and deep integration" by collaboratively building highly integrated "Smart Lab Units."


Recently, PRCXI, in collaboration with Nanjing Agricultural University and other institutions, launched the "Yao Wen" pesticide scientist intelligent agent—a landmark case exemplifying this model’s early success in agricultural science. This case demonstrates the immense potential of the closed-loop "AI Agent + Automated Platform" in addressing the pain points of "high investment and long cycles" in R&D.


This success stems from PRCXI's universal Smart Lab software platform and its cross-domain deep scenario understanding. It signifies that the company's business model has evolved from offering single-point products to delivering customizable, replicable systemic solutions. Currently, the company is extending this validated and mature model into more high-value R&D scenarios.


The fund under CICC Capital stated: "As life science enters the deep waters of digital and intelligent transformation today, breakthrough progress in the industry no longer relies solely on innovation in individual equipment or technologies but increasingly requires systemic solutions capable of integrating the entire workflow and possessing self-evolution capabilities. With its integrated 'AI + Hardware + Consumables + Services' approach, PRCXI delivers not just products, but a new and self-evolving form of scientific research productivity. The completion of this Series A+ financing marks the company’s critical leap from a product provider to an ecosystem builder for the 'Smart Lab.' With capital backing, PRCXI’s efforts to drive paradigm shifts in life science R&D are expected to enter a comprehensive fast lane."


Zhu Bin, founder of PRCXI, commented: "True intelligence goes beyond simply replacing manual labor; it reshapes R&D through deep AI empowerment, enabling higher and more stable product quality and achieving high-quality scalability. The core innovation of PRCXI’s 'Smart Lab' system lies in building a deep closed-loop of 'AI Agents + Automated Experiment Platforms.' This system provides comprehensive intelligent support for scientific research—from hypothesis generation and experimental design to process optimization—establishing a closed-loop framework of 'data-driven, autonomous decision-making, and iterative evolution,' thereby equipping labs with the capacity for continuous self-optimization."

Copyright © PRCXI Bioinformatics Co., Ltd. all rights reserved Web design